UK Blood Plasma Market Analysis

The UK Blood Plasma Market stood at around xx Bn in 2023 and is projected to reach US $xx Bn by 2033, exhibiting a CAGR of xx% during the forecast period.

The UK Blood Plasma Market Analysis Executive Summary

Plasma, also known as blood plasma, appears light-yellowish or straw-coloured. It serves as the liquid base for whole blood. Whole blood minus erythrocytes (RBCs), leukocytes (WBCs), and thrombocytes (platelets) make up the plasma. Every 2 seconds someone in the U.S. needs blood and or platelets. Approximately 29,000 units of red blood cells are needed every day in the U. S. 

The blood plasma market is expanding due to increasing demand for plasma-derived therapies, advancements in technology, and rising awareness of chronic diseases. Key products include immunoglobulins, clotting factors, and albumin, which are crucial for treating conditions like haemophilia and autoimmune disorders. The market is primarily driven by therapeutic and diagnostic applications in hospitals, clinics, and research institutions. North America leads in market share, followed by Europe and Asia-Pacific, which are also experiencing significant growth. Challenges such as supply chain management, regulatory compliance, and ethical concerns impact the industry, while opportunities lie in emerging markets and innovative therapies. Overall, the market is dynamic with substantial growth potential.    

UK Blood Plasma Market Dynamics

Market Growth Drivers

Some of the factors that will contribute include rising approval of Plasma products across the globe, also rising number of clinical researches that determines the safety and effectiveness of the products. Blood disorders like haemophilia and sickle cell anemia increase the need for plasma derived products. New policies for the promotion of plasma collection and increased public awareness about the benefits of plasma donations help the market. Recent improvements in the Plasma collection and processing make these therapies more effective and safer. As the healthcare expense grows across the world, especially in the developing nations, the growing research and development activities also open up new opportunities. Another factor that adds to the rise in consumption of plasma derivative products is the presence of senior citizens, a group that is most vulnerable to blood disorders. 

Opportunity

As for the future prospects of the blood plasma market, there may be continued development of the new methods of fractionation to increase the productivity of products, and expansion of emerging economies, such as Asia Pacific and Latin America. Having own plasma collection centres guarantees constant availability of raw material, while constant R&D may result in new treatments. The adoption of digital health technologies supports operational improvements, while partnerships with key stakeholders propel advancement. Emphasizing the efficiency of proposed solutions will be helpful for global healthcare systems, and sustaining highly effective plasma systems will enhance public health readiness in emergency situations. 

Market Restraints

Constraints that can slow down market growth and development include side effects arising from plasma-derived products, strict regulatory laws governing Industry and high production costs. Competition from other forms of treatment is another challenge; there would be few sources of donors as well. Perceptions and image factors, changes in the economic environment, and the technicalities of plasma collection and processing also pose challenges to the market. Mitigating these factors will therefore be critical in realizing sustainable growth and enhanced patient access to plasma derived products. 

Competitive Landscape Blood Plasma Market in UK

Key Players

• CSL Behring 
• Grifols
• Octapharma
• Kedrion Biopharma
• Biotest AG
• LFB 

Recent Developments

March 2024, Scientists invent a coin-sized device to rapidly isolate blood plasma for diagnostics and precision medicine.

February 2024, GC's 'Alyglo', first S. Korea FDA-approved blood plasma to launch in US from July.

May 2023,  PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru.

March 2023, CSL's $470 Million Plasma Fractionation Facility Opens in Marburg, Germany.

March 2022,  U.S. FDA Clears Terumo Blood and Cell Technologies' New Plasma Collection Technology.

Mergers and Acquisitions

February 2023, GC Biopharma acquired Catalyst Biosciences' rare disease hematology which includes "Marzeptacog alfa," an engineered factor VIIa that is ready for Phase 3 trials. This acquisition is intended to enhance GC Biopharma's presence in the blood plasma market, especially for treating rare bleeding disorders.

December 2023, Haier to Buy $1.8 Billion Stake in Chinese Blood Firm (1). 

Healthcare Policies and Regulatory Landscape for Blood Plasma Market in UK

Policy changes and Reimbursement scenario

Measures taken by the government for raising the level of plasma donation and the programs for the development of regional affordable blood product production are current strategies followed to cope with supply uncertainty and to increase the level of domestic production. The quality and safety of the products are regulated through legislation such as the WHO, and while it comes with some problems, problems for new entrants. This depends on the region; some regions have good coverage reimbursement policies while others have limited policies. Reimbursement system models aim at a new approach to payment for services, value-based care focuses on value for money, high production costs affect the prices. All the named factors influence the overall market developments in terms of availability, price, and utilization of plasma-derived therapies, which makes it necessary for actors to navigate such changes.